Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single- and Multiple-Dose Study to Assess the Safety and Pharmacokinetics of Ixekizumab (LY2439821) (Anti-IL-17 Humanized Antibody) in Chinese Patients With Psoriasis Vulgaris

Trial Profile

A Phase 1, Single- and Multiple-Dose Study to Assess the Safety and Pharmacokinetics of Ixekizumab (LY2439821) (Anti-IL-17 Humanized Antibody) in Chinese Patients With Psoriasis Vulgaris

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Ixekizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 20 Jan 2019 Planned End Date changed from 17 Jun 2019 to 14 May 2019.
    • 20 Jan 2019 Planned primary completion date changed from 17 Jun 2019 to 14 May 2019.
    • 21 Nov 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top